A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
3/6/2026
BreakingCataractEuropeSurgical
Oertli Launches OS 4 Up Dual-Function Cataract-Vitrectomy System
Switzerland-based Oertli announced Feb. 23 that its OS 4 Up dual-function cataract/vitrectomy machine is now available in all CE-certified markets. Features include adaptive energy delivery with Ph...
3/6/2026
BiosimilarsBreakingCataractEuropeIOLPharmaRetinaRevenueSurgicalUveitis
Ophthalmic Quarterly and 2025 Revenue for Carl Zeiss Meditec, Harrow, RxSight, ANI, and Xbrane
Million Carl Zeiss Meditec reported Feb. 12 that ophthalmology revenue for the last three months of 2025, the first quarter of its fiscal year 2025/2026, totaled €356.9 million ($419.2 million, con...
3/6/2026
BreakingCataractDealsSingle-UseSurgical
Rayner Acquires Distribution Rights to Anikavisc OVD in US
UK-based Rayner reported March 2 that it had acquired the US distribution rights to Anikavisc, an ophthalmic viscosurgical device (OVD), from Japan’s Visco Technologies Inc. Anikavisc, a cohesive f...
3/6/2026
BreakingCataractClinical TrialPharma
US FDA Gives Green Light to Phase III Trial of Harrow’s Triesence for Post-op Inflammation and Pain
Nashville, Tennessee-based Harrow reported on March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase III trial of Tri...
3/6/2026
BreakingCataractDealsFLACSLaserSurgical
Alcon-Lensar Deal Now Expected to Close in First Half of 2026
Alcon’s acquisition of Lensar is now on track to close in the first half of 2026, subject to customary conditions, including receipt of regulatory approval from the US Federal Trade Commission, Len...
3/6/2026
BreakingCell TherapyClinical TrialRegulationRetina
US FDA Gives Green Light to Phase I/II Trial of Sanaregen’s Retinal Cell Therapy Candidate
Sanaregen Vision Therapeutics reported March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of its retin...
3/6/2026
BiosimilarsBreakingEuropeRegulationRetina
Sandoz Reports EU Approval for Ranibizumab Biosimilar Branded Ranluspec
Swiss drugmaker Sandoz announced Feb. 23 that the European Commission had granted marketing authorization for Ranluspec, a ranibizumab biosimilar developed by India’s Lupin Limited. Sandoz holds ex...
3/6/2026
BreakingCell TherapyFundingGene TherapyRetina
Cirrus Expands to Singapore, Unveils GA Cell Therapy Candidate
Cirrus Therapeutics reported March 3 that it had established an R&D site in Singapore, expanding its presence in the Asia-Pacific region. The Cambridge, Massachusetts, company also unveiled a secon...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.